Product Description
Mechanisms of Action: HDAC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Bangladesh | Brazil | Colombia | Dominican Republic | Ecuador | France | Germany | Italy | Mexico | Peru | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: Arbutus Biopharma
Company Location: BURNABY A1 V5J 5J8
Company CEO: William Collier
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Osteoarthritis|Rotator Cuff Injuries|Arthritis, Infectious|Skin Diseases, Infectious
Phase 2: Biliary Tract Cancer
Phase 1: Melanoma|Colorectal Cancer|Oncology Hematological Unspecified|Oncology Unspecified|Pinealoma|Rhabdoid Tumor|Intestinal Diseases|Medulloblastoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
IMPACT | P1 |
Recruiting |
Medulloblastoma|Pinealoma|Rhabdoid Tumor |
2030-12-29 |
|
ChiCTR2400085261 | N/A |
Not yet recruiting |
Osteomyelitis |
2026-12-31 |
|
NEAR-TSA | N/A |
Recruiting |
Autism Spectrum Disorder |
2026-08-24 |
|
IHS | N/A |
Recruiting |
Migraine Disorders |
2026-01-01 |